All the Active Ingredient Drugs
Non-Nucleoside Reverse Transcriptase Inhibitors. Nevirapine (as anhydrous) 200 mg. TABS. (anhydrous): 60 x 200 mg. 1
tab×1/d for 14 days, follow. by 1
tab×2/d. in comb. with other
antiretrovir. ther.
For use in comb. with other antiretrov.
agents for the tmt. of HIV-1 infec. in
adults, adolescents, and child. of any age.
Most of the experience with Nevirapine is
in comb. with nucleoside reverse
transcriptase inhibitors (NRTIs). The
choice of a subsequent ther. after Nevirapine should be based on clinical
experience and resistance testing.
C/I: Hypersens., Readministr. to pts. who
required permanent discount. for severe
rash, rash accompanied by constitutional
sympts., hypersens. react., or clinical
hepatitis due to nevirapine, severe
hepatic impair. (Child-Pugh C) or pretreatment ASAT or ALAT > 5 ULN until
baseline ASAT/ALAT are stabilised < 5
ULN. Readministr. to pts who previous. had
ASAT or ALAT > 5 ULN during nevirapine ther. and had recur. of liver function abnormalit. upon readministr. of nevirapine, Coadministr. with herbal preparations containing St. John’s wort (Hypericum perforatum) due to risk of decreased plasma concentr. and reduced clinical effects of nevirapine.
